Despite slow progress, Boehringer keeps faith in oncology
The group highlights its ambitions in cancer again, but is at least two years away from launching a new product.
Embecta seeks high growth with low tech
The diabetes-focused Becton Dickinson spinoff intends to spend – but can it compete in insulin pumps?
Destiny’s date with a partner
The UK company insists that by the end of the year a partner will have been found for its microbiome project to prevent C difficile infections.
Novo makes a rare disease push
More deals could be in the offing, but gene therapy does not appear to be a big focus.
Intuitive faces down the competition
The robotic surgery giant is finally being challenged by companies even bigger than itself.
Liquid biopsy developers take aim at colorectal cancer
Natera and Guardant are about to shake things up with indication-specific blood tests, but Exact is keeping faith with Cologuard – for now.
No regrets as Lyell prepares for its first clinical trial
The preclinical company pulled off a giant flotation, and though its stock has since slumped it now has several years’ cash to play with.
Pacbio is in it for the long run
The sequencing sector is changing fast, but Pacbio believes its technology can hold out against its rivals.
Argenx’s independent streak approaches its biggest test
Armed with the first approval for an FcRn antagonist, the Belgian company’s chief executive remains convinced by a solo strategy.
